Abbott Receives EU CE Mark for Automated Version of BG Medicine's Galectin-3 Test | GenomeWeb

Abbott this week received an EU CE mark for its automated version of BG Medicine's Galectin-3 protein biomarker assay.

The assay, which is intended as an aid in determining the prognosis of heart failure patients, will run on Abbott's ARCHITECT immunochemistry platform.

BG received a CE Mark and US Food & Drug Administration 510(k) approval for a manual version of the Galectin-3 test in 2010 and has since worked with Abbott, Alere, Siemens, and BioMérieux on automated versions of the test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.